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Objective. The aim of this study was to evaluate the immunohistochemical expression of collagen IV, matrix
metalloproteinase (MMP) 9 and tissue inhibitor of MMP (TIMP) 2 in dentigerous cysts (DCs), radicular cysts (RCs),
keratocystic odontogenic tumors (KOTs), and ameloblastomas.
Study design. Twenty cases of DCs, 20 RCs, 20 KOTs, and 20 ameloblastomas were selected and analyzed by
immunohistochemistry.
Results. Most DCs and RCs showed continuous and 50% staining for collagen IV in the basement membrane of the
epithelium, whereas predominantly discontinuous thin and 50% staining was observed in KOTs and
ameloblastomas, with a significant difference in staining percentage (P  .001). MMP-9 was diffusely distributed and
localized in both epithelial and mesenchymal cells of all of the lesions analyzed. The staining percentage was higher
in the epithelium (P  .058) and mesenchyme (P  .005) of KOTs and ameloblastomas. Moreover, the distribution
pattern, location, and percentage of expression of TIMP-2 were similar in the lesions studied, except for
ameloblastoma, with a significant difference in staining percentage (P  .001).
Conclusion. These results demonstrate that the interaction between collagen IV, MMP-9, and TIMP-2 is an important
factor for the establishment of differences in the biologic behavior of the odontogenic cysts and tumors studied. (Oral
Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:468-475)Factors related to the epithelial and mesenchymal com-
ponents participate in the regulation of the growth of
odontogenic cystic lesions and tumors.1 The altered
expression of specific proteins of the extracellular ma-
trix (ECM), associated with the exuberant presence of
matrix metalloproteinases (MMPs) and the absence of
expression of metalloproteinase inhibitors (TIMPs),
may influence the behavior of these lesions. In the case
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468of tumors, this situation contributes to the growth and
higher aggressiveness of the tumor.2
The odontogenic keratocyst, recently reclassified as
keratocystic odontogenic tumor (KOT),3 is known for
its aggressive nature and high rate of recurrence, espe-
cially compared with other odontogenic cysts.4 Amelo-
blastoma is a locally aggressive benign epithelial odon-
togenic tumor with a marked invasion potential that
results in multiple recurrences after enucleation and
curettage.5 In contrast, dentigerous (DC) and radicular
(RC) cysts show an indolent behavior and rarely recur
after surgical removal. KOT presents a cystic structure
similar to that of DC and RC, but its invasive and
destructive growth is similar to that of ameloblastoma.6
KOT, ameloblastoma, DC, and RC show distinct
evolutions and biologic behaviors. In view of this fact,
a growing number of studies have tried to identify
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differences in behavior between these diseases. These
lesions arise from the remnants of odontogenesis,
which is controlled by the interaction between epithe-
lial and mesenchymal components.
Because odontogenic lesions sometimes mimic the
events related to the morpho- and histodifferentiation
necessary for tooth development, it is thought that
during tumorigenesis, epithelial-mesenchymal interac-
tions are also determinant for the evolution of these
lesions. However, according to Oliveira et al.,7 many
studies have investigated only the epithelial compo-
nents of odontogenic cysts and tumors.
The growth mechanism of odontogenic cysts, as well
as the invasion and destructive potential of some odon-
togenic tumors, might be influenced by the secretion of
MMPs, proteins that can be produced by both epithelial
and mesenchymal cells.8,9 Alaeddini et al.10 suggested
that for a better understanding of the biologic behavior
of these lesions, it is necessary to study the components
of the extracellular matrix (ECM) to identify differ-
ences in the distribution and expression of these pro-
teins between indolent cystic lesions and more aggres-
sive tumors.
In view of the above considerations, the objective of
the present study was to evaluate the immunohisto-
chemical expression of collagen IV, MMP-9, and
TIMP-2 in a series of cases of RC, DC, KOT, and
ameloblastoma in order to contribute to a better under-
standing of the role of these proteins in the biologic
behavior of these lesions.
MATERIAL AND METHODS
The sample consisted of 80 paraffin-embedded tissue
specimens comprising 20 cases of solid ameloblastoma,
20 KOTs, 20 DCs, and 20 RCs, obtained from the
Pathological Anatomy Service of the Discipline of Oral
Pathology, Department of Dentistry, Federal University
of Rio Grande do Norte (UFRN). The diagnoses of
odontogenic cysts and tumors were made using the
1992 and 2005 World Health Organization classifica-
tion criteria, respectively. The study was approved by
the Research Ethics Committee of UFRN.
Immunohistochemical methods
For immunohistochemistry, 3 m thick sections
Table I. Specifications of the antibodies used
Antibody Manufacturer Clone
Collagen IV Dako CIV22 Pepsin
MMP-9 NovoCastra 2C3 Citrate,
TIMP-2 NovoCastra 3A4 Citrate,were mounted on glass slides previously prepared withorganosilane adhesive (3-aminopropyltrithoxy-silane;
Sigma Chemical Co.) and submitted to the streptavidin-
biotin method. The histologic sections were deparaf-
finized in xylene and rehydrated in a decreasing alcohol
series. The sections were submitted to antigen retrieval
(Table I) and blockade of endogenous peroxidase with
10 volumes of hydrogen peroxide, washed in water, and
incubated with Tris-HCl, pH 7.4, for 10 minutes. Next,
the sections were incubated with the primary antibodies
(Table I) diluted in 1% bovine serum albumin (BSA)/
Tris-HCl, pH 7.4. The sections were then washed twice
in phosphate-buffered saline solution (PBS) and treated
with the labeled streptavidin biotin complex (LSAB;
Dako, Carpinteria, CA) at room temperature to bind the
primary antibodies. The reactions were developed with
0.03% diaminobenzidine (Liquid DAB Substrate;
Dako) as chromogen, and the slides were counter-
stained with Mayer hematoxylin for 10 minutes. Fi-
nally, the sections were dehydrated in alcohol and
cleared in xylene for mounting in Permount resin
(Fisher Scientific) under a coverslip. Liver and bladder
sections were used as positive control samples for
MMP-9 and TIMP-2, respectively. Immunostaining of
blood vessels in the basement membrane (BM) was
used as internal positive control for collagen IV. Sam-
ples treated as described above, except that the primary
antibody was replaced with a solution of BSA in PBS,
served as negative control samples.
Immunostaining was evaluated by 2 examiners at
different times under a light microscope. For collagen
IV, immunoreactivity was analyzed at the BM at the
epithelial/mesenchymal interface. Staining percentage
was analyzed semiquantitatively, as50% or50% of
the BM extension. The pattern of expression was eval-
uated according to continuity (continuous, discontinu-
ous) and thickness (thin, thick, and mixed thin and thick
areas) of staining at the BM.
The expression of MMP-9 and TIMP-2 was ana-
lyzed separately in the epithelial and mesenchymal
components. In the mesenchymal component, stain-
ing was detected in fibroblasts and endothelial and
inflammatory cells. Staining percentage was ana-
lyzed semiquantitatively according to the method of
Fregnani et al.11: 50% stained cells and 50%
stained cells. The distribution of staining was clas-
sified as focal and diffuse. The localization of stain-
ntigen retrieval Dilution Incubation
a 1%, 60 min, 37°C, steamer 1:50 120 min
, 30 min, steamer 1:20 Overnight
, 30 min, steamer 1:50 OvernightA
pH 1.8
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layer.
Immunohistochemical staining of collagen IV,
MMP-9, and TIMP-2 was evaluated by descriptive and
semiquantitative methods. Statistical analysis was per-
formed using the SPSS for Windows program, version
7.0 (SPSS, Chicago, IL). The 2 test was used to
compare epithelial and mesenchymal staining. A P
value of .05 was considered to indicate statistical
significance.
RESULTS
Most DCs (65%) and RCs (55%) exhibited continu-
ous staining for collagen IV in the BM of the epithe-
lium (Fig. 1, a and b), whereas discontinuous staining
predominated in KOTs (60%) and ameloblastomas
(75%) (Fig. 1, c and d). Staining appeared thick or
mixed in 70% of DCs and thin in 75% of RCs, 60% of
KOTs, and 75% of ameloblastomas. The percentage of
collagen IV expression differed significantly between
lesions (P  .001). Immunostaining 50% was ob-
served in 70% of DCs and immunostaining 50% in
55% of RCs. The lowest staining percentage was ob-
Fig. 1. Immunohistochemical staining of collagen IV at the b
(RC), (c) keratocystic odontogenic tumor (KOT), and (d) ame
observed in DC and RC. c, Note linear, discontinuous, th
characteristic of ameloblastoma.served for KOTs and ameloblastomas, with immuno-staining 50% in 80% and 100% of the lesions, re-
spectively (Table II).
Expression of MMP-9 was mainly diffuse in the
epithelial and mesenchymal component of 100% of
the lesions studied. There was minimal variation in the
pattern of localization of stained cells. In the epithe-
lium, staining was observed in all layers of 95% of DCs
and 90% of RCs (Fig. 2, a and b), whereas in KOTs
positive staining was detected throughout the epithe-
lium in 100% of cases (Fig. 2, c). In ameloblastomas,
staining was detected in both peripheral cells and in the
center of islands of the neoplastic epithelium (Fig. 2, d).
A staining percentage 50% predominated in all le-
sions studied, with a trend to higher expression in
KOTs (90%) and ameloblastomas (95%) compared
with DCs (65%) and RCs (75%). However, there was
no statistically significant difference (P  .058; Table
II). Mesenchymal staining was observed in fibroblasts
and inflammatory and endothelial cells in all cases
studied. Regarding the expression of MMP-9 in the
mesenchyme, staining percentage 50% was higher in
ameloblastomas (70%) and KOTs (40%), whereas only
25% of RCs and 20% of DCs exhibited 50% stained
nt membrane in (a) dentigerous cyst (DC), (b) radicular cyst
oma (400). Strong, thick continuous and linear deposit was
osit in KOT. d, Linear discontinuous and thin deposit isaseme
loblast
in depcells (P  .05; Table II).
tic odo
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except for ameloblastoma. The distribution of staining
was diffuse in the epithelium and connective tissue of
100% of DCs, RCs and KOTs (Fig. 3, a-c), whereas in
Fig. 2. Immunohistochemical expression of MMP-9 (400).
dentigerous cyst (DC), (b) radicular cyst (RC), (c) keratocys
Table II. Immunohistochemical expression of collagen
cyst (DC), keratocystic odontogenic tumor (KOT), and
Protein
Le
RC DC K
Collagen IV
1%-50% 11 (55%) 6 (30%) 16 (
50% 9 (45%) 14 (70%) 4 (
MMP-9 (epithelium)
1%-50% 7 (35%) 5 (25%) 2 (
50% 13 (65%) 15 (75%) 18 (
MMP-9 (mesenchyme)
1%-50% 15 (75%) 16 (80%) 12 (
50% 5 (25%) 4 (20%) 8 (
TIMP-2 (epithelium)
1%-50% 1 (5%) 0 (0%) 0 (
50% 19 (95%) 20 (100%) 20 (
TIMP-2 (mesenchyme)
1%-50% 0 (0%) 1 (5%) 6 (
50% 20 (100%) 19 (95%) 14 (ameloblastomas focal staining was observed in the ep-ithelium of 55% of cases and diffuse staining in the
connective tissue of 80% (Fig. 3, d). Positive staining
of all epithelial cell layers was observed in 100% of
DCs and RCs and in 95% of KOTs. In ameloblastomas,
the diffuse staining in the epithelium and mesenchyme in (a)
ntogenic tumor (KOT), and (d) ameloblastoma.
MP-9, and TIMP-2 in radicular cyst (RC), dentigerous
oblastoma
(%)
2 P valueAmeloblastoma Total
20 (100%) 53 (66.3%) 24.766 .001
0 (0)%) 27 (33.8%)
1 (5%) 15 (18.8%) 7.467 .058
19 (75%) 65 (81.3%)
6 (30%) 49 (61.3%) 12.798 .005
14 (70%) 31 (38.8%)
9 (45%) 10 (12.5%) 26.057 .001
11 (55%) 70 (87.5%)
11 (55%) 11 (55%) 22.079 .001
9 (45%) 9 (45%)NoteIV, M
amel
sion, n
OT
80%)
20%)
10%)
90%)
60%)
40%)
0%)
100%)
30%)
70%)staining of peripheral epithelial cells and cells in the
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Mesenchymal staining was observed in fibroblasts and
inflammatory and endothelial cells in all cases studied.
The percentage of TIMP-2 staining in the epithelium
was 50% in most lesions (100% DCs, 95% RCs, and
100% KOTs), whereas 50% stained cells were ob-
served in only 55% of ameloblastomas (P  .001;
Table II). In the mesenchyme,50% stained cells were
observed in 95% of DCs and in 100% of RCs and
KOTs, whereas 55% of cases of ameloblastoma pre-
sented 50% stained cells (P  .001; Table II).
DISCUSSION
KOT, ameloblastoma, DC, and RC present distinct
evolutions and biological behaviors. Despite the cystic
structure of KOT, some studies emphasize the similar-
ity in the behavior of these cysts to the ameloblastoma
in view of their invasive growth and destructive poten-
tial.6
Several factors have been associated with the aggres-
sive behavior of ameloblastomas, such as an increased
proliferation potential,12 alterations in the expression of
tumor suppressor genes, and the aberrant expression of
cell cycle–regulating proteins,13 adhesion molecules,14
Fig. 3. Immunohistochemical expression of TIMP-2 (400).
dentigerous cyst (DC), (b) radicular cyst (RC), and (c) kerato
and stroma of ameloblastoma were focal.and MMPs and their inhibitors (TIMPs).15 In addition,Silveira et al.8 suggested that the mechanism of expan-
sion of KOTs, DCs, and RCs may also be influenced, or
even be conducted, by the secretion of MMPs. Thus, an
exuberant expression of MMPs might be related to a
higher aggressiveness of cystic lesions.
MMP-9 is known to play an important role in BM
degradation owing to its ability to degrade collagen IV,
the main BM component. However, a balanced action
of activators and inhibitors of MMPs is necessary so
that these proteins can exert their function. In this
respect, TIMPs inhibit the active forms of MMPs.16 On
the basis of these observations it could be suggested
that the degradation of ECM is not dependent on the
expression of a single MMP, but rather that the com-
bined action of several MMPs and TIMPs is essential
for the efficient degradation of the BM and interstitial
stroma. Kumamoto et al.15 performed an immunohis-
tochemical study and found that increased expression
of TIMP-1 and TIMP-2 was related to weak immuno-
reactivity for MMP-9. According to those authors, it is
possible that the TIMPs contribute to suppress tumor
progression in ameloblastomas through the inhibition
of MMP-9 activity.
Within this context, the evaluation of the expression
the staining diffuse in the epithelium and mesenchyme in (a)
odontogenic tumor (KOT). d, The staining in the epitheliumNote
cysticof collagen IV, MMP-9, and TIMP-2 may contribute to
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these odontogenic lesions. ECM proteins have been
detected in several odontogenic cysts and tu-
mors,7,8,17-19 but no investigation has explored the re-
lationship between collagen IV, MMPs, and TIMPs in
odontogenic cysts and tumors.
In the present study, a lower expression of collagen
IV was observed in KOT and ameloblastoma. A pos-
sible explanation is that a higher degradation or a
reduced synthesis of this protein occurred in these
lesions. We speculate that both increased degradation
and reduced synthesis of collagen may influence the
aggressiveness of the lesions. A higher capacity to
degrade the BM and other ECM components has been
associated that with a higher destructive potential of the
lesions.20 According to Nagatsuka et al.,17 the expres-
sion of collagen IV may be correlated with the growth
and aggressiveness of odontogenic cysts and tumors.
In normal and benign tissue, collagen IV has been
reported to appear in a continuous, thick and strongly
stained linear pattern.21,22 In the present study, RCs,
and DCs generally exhibited a linear and continuous
expression of collagen IV, in agreement with the stain-
ing pattern described for normal tissues. On the other
hand, KOTs and ameloblastomas presented a highly
discontinuous thin linear staining pattern, with 50%
extension of the BM in 80% and 100% of cases, re-
spectively. This finding might be related to the pro-
liferative potential of these odontogenic tumors. The
loss of BM integrity is known to favor alterations in
epithelial-mesenchymal interactions that contribute
to the mechanisms of cell differentiation and tumor
proliferation.7,23
Regarding the thickness of collagen IV staining, RCs
presented an irregularity compared with the staining
seen in DCs. Most RCs (75%) exhibited a thin line,
whereas staining in DCs was characterized by thick and
thin areas in 70% of specimens. It is therefore thought
that in RCs the inflammatory infiltrate, which is a
determinant component of the lesion, contributed to the
lower expression of collagen IV, because those cells
showed high staining percentage for MMP-9. On the
other hand, the presence of an inflammatory infiltrate is
a common finding in DCs, and MMP-9 secretion was
possibly lower, a fact explaining the regular and thick
collagen IV staining.
The percentage of collagen IV staining was more
pronounced in DCs than in RCs, KOTs and ameloblas-
tomas. However, 45% of RC cases showed a staining
percentage similar to that of DCs. Therefore, the pres-
ent results suggest that the weak expression of collagen
IV, mainly observed in KOTs and ameloblastomas,
may induce changes in the interaction between theepithelium and mesenchyme, contributing to the more
aggressive growth of these lesions.
In agreement with the findings of the present study,
Oliveira et al.7 observed differences in the composition
of the BM of RCs, DCs, and KOTs. Those authors
observed continuous and intense expression of collagen
IV in RCs. On the other hand, KOTs exhibited thin,
linear, markedly discontinuous and weak staining. Ac-
cording to those authors, the epithelial component of
KOTs has a higher proliferative capacity than that of
DCs and RCs, a fact supporting the distinct biologic
behavior of those lesions. In addition, it is possible that
this BM irregularity shown by KOTs favors the con-
stant shedding of epithelial cells from the capsule and
may be related to the higher recurrence rates of these
tumors. Although consensus exists regarding the rela-
tionship between BM integrity and aggressiveness of
the lesion, Poomsawat et al.19 found no association
between the expression of BM components (laminin 1
and 5, collagen IV, and fibronectin) in RCs, DCs, and
KOTs and the biologic behavior of these lesions.
Therefore, in view of the functions of the BM, espe-
cially its involvement in the control of cell prolifera-
tion, differentiation, and invasion, it is evident how
much these processes are altered in KOTs and amelo-
blastomas, a fact that can explain the more aggressive
behavior of these tumors compared with RCs and DCs.
Considerable research effort has been devoted to the
MMP subfamily of gelatinases/type IV collagenases,
including MMP-2, referred to as gelatinase-A, and
MMP-9, referred to as gelatinase-B, because of their
ability to degrade type IV collagen and gelatins.15 Ex-
pression of gelatinases/type IV collagenases has been
investigated in numerous tumors and has been shown to
be associated with an invasive phenotype and meta-
static potential of tumor cells.24,25 Preclinical trials
have shown that squamous cell carcinomas express
high levels of MMPs in vivo and that the inhibition of
these enzymes in vitro and in animal models reduces
the invasion potential and metastatic capacity of the
tumor.2
Regarding the expression of MMP-9 in odontogenic
cysts and tumors, in the present study epithelial and
mesenchymal cells of the lesions studied diffusely se-
creted this protein. This finding suggests a role of
MMP-9 in tumor growth, because the protein is known
to act on the remodeling of ECM and the degradation of
bone matrix.26,27 However, the staining percentage of
MMP-9 in the epithelial and mesenchymal component
was markedly higher in KOTs and ameloblastomas
than in RCs and DCs, with a staining percentage50%
being observed in 90% and 95% of cases, respectively.
These findings suggest that the growth of these lesions
is influenced by the secretion of MMPs. Therefore, the
OOOOE
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genic tumors analyzed suggest a possible participation
of this protein in cell proliferation and differentiation
and may explain the greater bone resorption, higher
invasion potential, and poorer prognosis compared with
DC and RC.11 The immunoreactivity to MMP-9 seen in
both the epithelium and the mesenchyme of these le-
sions can be explained by the fact that the protein is
produced by epithelial cells, fibroblasts, macrophages,
plasma cells, lymphocytes, and neutrophils.28
According to Vicente et al.,16 MMP-2 and MMP-9
are involved in angiogenesis and tumor growth, a fact
suggesting an association of these gelatinases with the
aggressive behavior and unpredictable clinical course
of some human neoplasms. Similarly to the present
study, Silveira et al.8 observed more pronounced ex-
pression of MMP-9 in the mesenchymal component of
KOTs compared with RCs and DCs, a finding support-
ing the hypothesis of a more aggressive behavior of this
tumor compared with other cysts. In the study by Ku-
mamoto et al.,15 immunoreactivity to MMP-9 was
stronger in the stroma of ameloblastomas than in the
mesenchymal component of tooth germs, suggesting
that an increased production of this protein by neoplas-
tic cells is related to the transformation of odontogenic
tissues and aggressiveness of this tumor. Ribeiro et al.29
also found intense immunostaining for this gelatinase in
the parenchyma and stroma of ameloblastomas, indi-
cating its possible participation in the growth of these
tumors.
Curiously, combined analysis of the present results
showed that KOTs and ameloblastomas, which pre-
sented higher expression of MMP-9 in epithelial and
mesenchymal components, also exhibited low expres-
sion of collagen IV, which may result from higher BM
degradation or reduced synthesis of collagen IV. We
think that these findings suggest higher BM degradation
in consequence of high expression of MMP-9. Some
reports in the literature show that MMP-9 plays an
important role in the degradation of the BM as a result
of its ability to degrade collagen IV.16
Nagase et al.30 and Verma and Hansch31 demon-
strated that MMPs are weakly expressed by tissues
under physiologic conditions, whereas high expression
of these proteins is observed in neoplastic tissues, ow-
ing to an imbalance in the activity of MMPs and their
inhibitors (TIMPs). In the present study, high percent-
age and diffuse expression of TIMP-2 was observed in
epithelial and mesenchymal cells of DCs, RCs, and
KOTs. In contrast, focal staining was detected in
ameloblastomas, a finding possibly implying lower se-
cretion of this protein which inhibits the activity of
MMP-9. Similarly, the staining percentage was less
pronounced in the epithelial and stromal components ofameloblastoma compared with the other lesions, a find-
ing suggesting higher production of MMP-9, increased
BM degradation and the consequent higher invasion
potential of this tumor. Siqueira et al.32 observed in-
tense and diffuse TIMP-2 staining in ameloblastomas,
which was associated with lower aggressiveness of the
tumor. In an in vitro study, Wang et al.5 showed that
overexpression of TIMP-2 in ameloblastoma cells was
associated with the suppression of MMP-2 activity and
a consequently lower invasion potential. It is believed
that TIMP-2 suppresses tumor invasion by inhibiting
MMPs.33 Taken together, these studies suggest that in
the present series, the lower expression of TIMP-2 in
ameloblastomas might be an indicator of the more
aggressive behavior of this tumor compared with the
other lesions studied, a fact supported by the higher
expression of MMP-9.
The higher expression of TIMP-2 in DCs and RCs
seems to be the result of a lower activity of MMP-9 and
lower BM degradation, which is compatible with the
more indolent behavior of these lesions. The balance
between MMPs and TIMPs ultimately determines the
extent of ECM degradation under physiologic and
pathologic conditions.34 These features suggest that
TIMP-2 may suppress tumor progression in ameloblas-
tomas.
Immunoreactivity to MMP-9 and TIMP-2 was ob-
served in the epithelial and mesenchymal components
of all odontogenic lesions studied herein. This finding
suggests that, similar to odontogenesis, epithelial-mes-
enchymal interactions are determinant for the regula-
tion of the growth of cystic lesions and for tumor
progression.
In conclusion, the present results suggest an interac-
tion between the production of MMP-9 and TIMP-2
and the degradation of BM components, which may
contribute to the distinct biologic behavior of amelo-
blastomas and KOTs compared with DCs and RCs.
Ameloblastomas and KOTs demonstrate higher pro-
duction of MMP-9 and increased degradation or re-
duced synthesis of collagen IV. The expression of these
molecules may serve as an indicator of the degree of
local aggressiveness of these odontogenic cysts and
tumors.
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